Novo Nordisk is trading $48.33 (+3.01%) after JPMorgan raised its 2026 sales forecast and price target.
- Wegovy forecasts increased 7% to 82 billion Danish kroner
- Stronger-than-expected Wegovy growth was reported outside the United States
- Limited generic erosion affecting Ozempic supported the company-specific rally